Site icon NorthEast Now

Union home minister Amit Shah hails DCGI’s approval of Serum Institute, Bharat Biotech’s Covid19 vaccines

Covaxin Covishield

Union home minister Amit Shah has hailed the approval granted on Sunday by the Drugs Controller General of India (DCGI) to the COVID19 vaccines of the Serum Institute of India (SII) and Bharat Biotech.

In a tweet on Sunday, Union home minister Shah said, “A momentous achievement for India!”

Ready for a challenge? Click here to take our quiz and show off your knowledge!

“I salute our very talented and hardworking scientists for making India proud,” Shah said.

Also read: DCGI finally approves Serum Institute, Bharat Biotech’s COVID19 vaccines for emergency use

“Congratulations to Prime Minister Shri Narendra Modiji for striving towards a COVID free India. Visionary leadership can make a huge difference,” he said.

Ready for a challenge? Click here to take our quiz and show off your knowledge!

“The approval to Made in India vaccines will prove to be a game changer in boosting Prime Minister Narendra Modi’s vision of an Aatmanirbhar Bharat.”

“We heartily thank our scientists, doctors, medical staff, security personnel and all Corona warriors who dedicatedly served humanity during these testing times,” Shah added.

“Nation will always remain grateful to them for their selfless service towards mankind,” he said.

The Drugs Controller General of India (DCGI) on Sunday approved the Covid19 vaccines, developed by the Serum Institute of India (SII) and Bharat Biotech, for emergency use.

The Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) met on January 1-2, 2021 and made recommendations in respect of proposal for restricted emergency approval of COVID19 virus vaccine of SII and Bharat Biotech.

After adequate examination, Central Drugs Standard Control Organisation (CDSCO) has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial, the Union health ministry said.

 

Exit mobile version